Malignancies Clinical Trials in Shanghai, Shanghai Municipality
14 recruitingShanghai, Shanghai Municipality, China
Showing 1–14 of 14 trials
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 1Phase 2
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc255 enrolled1 locationNCT07299747
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1Phase 2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Phase 1
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors
Solid Tumor Malignancies
Beijing StoneWise Technology Co., Ltd60 enrolled1 locationNCT07363967
Recruiting
Not Applicable
Exploratory Trial of Navigational Bronchoscopy-Guided Cryoablation in Lung Cancer Treatment
Lung Malignancies
Tianjin Puli Ark Medical Technology Co., Ltd.40 enrolled2 locationsNCT07301411
Recruiting
Phase 1
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd.32 enrolled6 locationsNCT07128914
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 1
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.191 enrolled22 locationsNCT05728658
Recruiting
Phase 1
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
Advanced Hematologic Malignancies
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.114 enrolled3 locationsNCT07113925
Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
Gastrointestinal Malignancies
Ruijin Hospital40 enrolled1 locationNCT06644274
Recruiting
Phase 1
A Study of IBI363 in Subjects With Advanced Malignancies
Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.556 enrolled1 locationNCT06468098